Exercise effects in Polycythemia Vera patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how exercise affects people with Polycythemia Vera (PV), a blood condition that makes too many red blood cells. If you have PV with a JAK2 V617F mutation and want to start regular physical activity, you may be able to join to help researchers understand your body's response to exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 69 years old.
- Have confirmed polycythemia vera (PV) with a JAK2 V617F mutation and have been prescribed a cardiopulmonary exercise test (CPET) because you want to start regular physical activity.
- Not have any known heart or chronic lung disease (like asthma) that could affect your exercise ability, separate from PV.
- Not have had a major blood clot in the past.
- Have a body mass index (BMI) under 35.
- Be covered by French social security and not be under legal protection, psychiatric care, or deprived of liberty.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
This study looks at how thick your blood is (blood viscosity) if you have polycythemia, a condition where your body makes too many red blood cells. It aims to understand the relationship between blood thickness and your red blood cell levels.
This trial studies proteins and red blood cell production in people with polycythemia (high red blood cell count) to understand its causes. It may help improve care for patients with this condition.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Hear when a new Polycythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.